The FDA has approved AbbVie’s supplemental new drug application for Rinvoq (upadacitinib) to treat inflammatory bowel disease ...

The label update provides an option for patients who have received at least 1 approved systemic therapy if TNF blockers are clinically inadvisable.

Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom ...

At 24/7 Wall St., we have closely followed dividend-paying stocks for over 15 years. With a growing audience of savvy Baby ...

Actor Lee Dong-gun was diagnosed with "ankylosing spondylitis," a rare and incurable disease that affects only 1% of South Korea’s population. On the 28th, SBS’s *My Little Old Boy* broadcasted Lee’s ...

Thanks to new settlement agreements with three generic drug makers, Gilead Sciences has extended the expected life span of its flagship HIV treatment Biktarvy by as many years. Gilead has struck ...

Eli Lilly stock (NYSE: LLY) should be on your radar. Here’s why – it is presently trading within the support range ($688 – $761), price points from which it has previously bounced significantly. Over ...

AbbVie is a Dividend King with solid growth prospects. Enterprise Products Partners offers a juicy distribution that's sustainable. Coca-Cola is an iconic dividend stock that should be a safe haven if ...

AbbVie has a roughly 3% yield, limited patent cliff risk, and an aesthetic niche that has long legs. Coca-Cola has a roughly 3.1% yield, a well-run business, and an attractive valuation. Chevron has a ...

Share on Pinterest Consuming a little over 1 can of diet or regular soda per day may increase liver disease risk, a new study suggests. Image credit: SKC/Stocksy Diet versions of beverages are often ...